Navigation Links
Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Date:9/19/2011

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first patient was dosed in the Company's Phase I clinical trial of its lead drug candidate ME-143 in patients with refractory solid tumors. The trial, conducted in collaboration with the Sarah Cannon Research Institute, is expected to enroll up to 24 patients with final data collected by the second quarter of 2012.

Fiscal Year End Conference Call

Marshall Edwards also announced that its management team will host a conference call with simultaneous webcast on Thursday, September 29, 2011, beginning at 5:00 p.m. Eastern time. Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an overview of the Company; Robert Mass, MD, Chief Medical Officer, will discuss the Company's lead oncology drug candidates, including an update on the Phase I clinical trial of ME-143; and Thomas Zech, Chief Financial Officer, will provide a summary of the Company's fiscal year ended June 30, 2011 financial results.

To access the live call, please dial 866-800-8652 (toll-free) or 617-614-2705 (international), participant passcode 14784577. A replay of the call will be available approximately two hours after the conclusion of the call. To access the replay, please dial 888-286-8010 (toll-free) or 617-801-6888 (international), passcode 99793585. The conference call will also be webcast live and can be accessed at www.marshalledwardsinc.com/investor. Please connect several minutes prior to the start of the webcast to ensure adequate time for any software downloads that may be required.

About the Phase I Clinical Trial of ME-143

The Phase I trial of ME-143 was initiated earlier
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards to Host Annual Meeting of Stockholders
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Announces Private Placement
7. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
8. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... 31, 2015  CVS Health (NYSE: CVS ... clinical affiliations with Rush University Medical Center in ... Medical Center in Tucson, Arizona ... Care. These affiliations will help enhance access to ... these clinical affiliations, CVS Health will provide prescription ...
(Date:3/31/2015)...  Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company ... today Oxis CEO Tony Cataldo has requested ... on the Euronext exchange. Oxis shares will continue to ... Oxis Chairman and CEO Tony Cataldo ... its strategies launched in 2014 and 2015, we must ...
Breaking Medicine Technology:Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Calif., June 24, 2011 ... a global leader in the field of radiation oncology, ... Trade Agreement (KORUS FTA), which is currently pending Congressional ... opportunities for U.S. exporters nationwide, the agreement, if ratified, ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and ... ALKS ) today announced results from an analysis ... diabetes medication BYDUREON™ (exenatide extended-release for injectable suspension) was not ... 2 diabetes. These findings will be presented in a poster ...
Cached Medicine Technology:Accuray Hosts Korean Embassy's Minister for Economic Affairs at Event to Support the U.S.-Korea Free Trade Agreement 2Accuray Hosts Korean Embassy's Minister for Economic Affairs at Event to Support the U.S.-Korea Free Trade Agreement 3Accuray Hosts Korean Embassy's Minister for Economic Affairs at Event to Support the U.S.-Korea Free Trade Agreement 4Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 2Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 3Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 4Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 5Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 6Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 7Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011 8
(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 In ... (ADS) is offering advice for buying from a ... Dealers Association (NMEDA) is a nonprofit organization that ... in the manufacturing and installation of mobility equipment. ... in the industry that consistently adhere to the ...
(Date:3/31/2015)... Calling all runners, walkers and everyone who ... diseases! The first annual “Lyme Walk & Run” will be ... CT. The event, hosted by Lyme Research Alliance (LRA) ... to support research and education about Lyme and other tick-borne ... and abilities, will feature 5K and 10K runs and one-mile ...
(Date:3/31/2015)... Hollywood, Florida (PRWEB) March 31, 2015 ... that activities like basketball, rock climbing, and cycling are ... called Adaptive Sports at Memorial Rehabilitation Institute aims to ... the Memorial Healthcare System, will host an Adaptive Sports ... p.m.) at Memorial Regional Hospital South in Hollywood. ...
(Date:3/31/2015)... NB (PRWEB) March 31, 2015 Indosoft, developer ... of Asterisk 1.4 support in development of their 5.x line. ... for Asterisk has been deployed around the world for more ... Asterisk 1.4 as a telephony platform, Q-Suite can fully embrace ... providing quality call center software on Asterisk for more than ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2
... person with a disability, MINNEAPOLIS, Nov. 6 ... recipient of the 2008 Judd Jacobson Memorial Award.,Established in ... pursuit or achievement in a business entrepreneurial,endeavor by a ... Kusiak, 48, is a paraplegic as the result of ...
... 2008 A major issue in the development of ... damaged tissues. In a review of the issue published ... regeneration in humans from the body,s own tissues by ... answered before the process can reach clinical status. , ...
... ResMed Inc. (NYSE: RMD ),today announced record ... 2008. Revenue for the quarter was $217.9 million, a ... the current,quarter, income from operations was $36.6 million and ... 16%, respectively, compared to the quarter,ended September 30, 2007. ...
... mass maintenance, study finds , , THURSDAY, Nov. 6 (HealthDay ... bones, which can lead to a decrease in bone ... In previous research, the study authors, from Loyola University ... rats large amounts of alcohol caused significant decreases in ...
... 915, BALTIMORE, Nov. 6 The following ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ), WHEN: Tuesday, ... outside the Baltimore Marriott Waterfront Hotel, 700,Aliceanna St., ... Maryland Right to Life, Defend Life and the,Catholic ...
... the Innovative Program Targeting Adolescents, PHILADELPHIA, ... (AHIP) will recognize Independence Blue Cross (IBC) ... adolescents to get the,important, recommended immunizations they ... against dangerous, infectious diseases like,meningitis and HPV, ...
Cached Medicine News:Health News:Wisconsin Farmer Ronald Kusiak Honored With 2008 Jacobson Memorial Award 2Health News:New advancements in the use of adult, embryonic stem cells for tissue regeneration 2Health News:New advancements in the use of adult, embryonic stem cells for tissue regeneration 3Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008 7Health News:Alcohol Abuse Can Damage Bones 2Health News:Coalition Asks Bishops to Take Politicians to Task 2Health News:Independence Blue Cross Honored for Immunization Program 2Health News:Independence Blue Cross Honored for Immunization Program 3
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... System is the smallest blood glucose testing system ... you need it in your backpack or ... in your purse or pocket.* Its small size ... And, because it's so convenient it's easier for ...
... Carl Zeiss is expanding the ... of field, excellent color reproduction, high-contrast ... New patented optics provide improved resolution ... SyCoP (Systems Control Panel) combines all ...
Medicine Products: